Cargando…

Integration of PARP-inhibitors in ovarian cancer therapy

Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pietragalla, Antonella, Ciccarone, Francesca, Nero, Camilla, Scambia, Giovanni, Lorusso, Domenica, Daniele, Gennaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400691/ https://www.ncbi.nlm.nih.gov/pubmed/36046198 http://dx.doi.org/10.37349/etat.2020.00011

Ejemplares similares

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
por: Duranti, Simona, et al.
Publicado: (2021)

Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment
por: Nero, Camilla, et al.
Publicado: (2021)

Immunotherapy in gynecological cancers
por: Lorusso, Domenica, et al.
Publicado: (2021)

PTEN and Gynecological Cancers
por: Nero, Camilla, et al.
Publicado: (2019)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine
por: Nero, Camilla, et al.
Publicado: (2021)

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

The Role of Artificial Intelligence in Managing Multimorbidity and Cancer
por: Cesario, Alfredo, et al.
Publicado: (2021)

Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital
por: Bizzarri, Nicolò, et al.
Publicado: (2021)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
por: Banerjee, Susana, et al.
Publicado: (2020)

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
por: Falcone, Rosa, et al.
Publicado: (2022)

Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center
por: Nero, Camilla, et al.
Publicado: (2022)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Epigenetic Insights on PARP-1 Activity in Cancer Therapy
por: Pinton, Giulia, et al.
Publicado: (2022)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor scheduling
por: Strobl, Maximilian, et al.
Publicado: (2023)

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study)
por: Nero, Camilla, et al.
Publicado: (2020)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
por: Boussios, Stergios, et al.
Publicado: (2019)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

PARP Inhibitors in Ovarian Cancer: A Review
por: O’Malley, David M., et al.
Publicado: (2023)

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
por: Duranti, Simona, et al.
Publicado: (2021)

Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
por: Musacchio, L., et al.
Publicado: (2022)

New treatment option for ovarian cancer: PARP inhibitors
por: Meehan, Robert S., et al.
Publicado: (2016)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective
por: Loizzi, Vera, et al.
Publicado: (2020)

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
por: Jiang, Xuan, et al.
Publicado: (2019)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
por: Xu, Jing, et al.
Publicado: (2022)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
por: Agostinelli, Veronica, et al.
Publicado: (2023)

Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers
por: Hatamikia, Sepideh, et al.
Publicado: (2023)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l1r7itj456ekeefock36duevh7